Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
J Orthop Surg Res ; 17(1): 137, 2022 Mar 04.
Artigo em Inglês | MEDLINE | ID: mdl-35246197

RESUMO

BACKGROUND: Bone marrow mesenchymal stem cells have always been a heated research topic in bone tissue regeneration and repair because of their self-renewal and multi-differentiation potential. A large number of studies have been focused on finding the inducing factors that will promote the osteogenic differentiation of bone marrow mesenchymal stem cells. Previous studies have shown that macrophage exosomes or miRNA-26a-5p can make it work, but the function of this kind of substance on cell osteogenic differentiation has not been public. METHODS: M2 macrophages are obtained from IL-4 polarized bone marrow-derived macrophages. Exosomes were isolated from the supernatant of M2 macrophages and identified via transmission electron microscopy (TEM), western blotting, and DLS. Chondrogenic differentiation potential was detected by Alcian blue staining. Oil red O staining was used to detect the potential for lipogenic differentiation. And MTT would detect the proliferative capacity of cells. Western blot was performed to detect differential expression of osteogenic differentiation-related proteins. RESULTS: The results showed that M2 macrophage exosomes will promote bone differentiation and at the same time inhibit lipid differentiation. In addition, M2 macrophage-derived exosomes have the function of promoting the expression of SOX and Aggrecan suppressing the level of MMP13. The exosome inhibitor GW4689 suppresses miRNA-26a-5p in M2 macrophage exosomes, and the treated exosomes do not play an important role in promoting bone differentiation. Moreover, miRNA-26a-5p can enable to promote bone differentiation and inhibit lipid differentiation. miRNA-26a-5p can promote the expression of ALP (alkaline phosphatase), RUNX-2 (Runt-related transcription factor 2), OPN(osteopontin), and Col-2(collagen type II). Therefore, it is speculated that exosomal miRNA-26a-5p is indispensable in osteogenic differentiation. CONCLUSIONS: The present study indicated that M2 macrophage exosomes carrying miRNA-26a-5p can induce osteogenic differentiation of bone marrow-derived stem cells to inhibit lipogenic differentiation, and miRNA-26a-5p will also promote the expression of osteogenic differentiation-related proteins ALP, RUNX-2, OPN, and Col-2.


Assuntos
Células-Tronco Mesenquimais , MicroRNAs , Osteogênese/genética , Diferenciação Celular , Humanos , Lipídeos , Células-Tronco Mesenquimais/metabolismo , MicroRNAs/genética , MicroRNAs/metabolismo
2.
Biomed Res Int ; 2021: 7218067, 2021.
Artigo em Inglês | MEDLINE | ID: mdl-34926690

RESUMO

Macrophages are commonly classified as M1 macrophages or M2 macrophages. M2 macrophages are obtained by stimulation of IL-4 with anti-inflammatory and tissue repair effects. Exosomes are 30-150 nm lipid bilayer membrane vesicles derived from most living cells and have a variety of biological functions. Previous studies have shown that macrophage exosomes can influence the course of some autoimmune diseases, but their effect on knee osteoarthritis (KOA) has not been reported. Here, we analyze the roles of exosomes derived from M2 macrophage phenotypes in KOA rats. Exosomes were isolated from the supernatant of M2 macrophages and identified via transmission electron microscopy (TEM), Western blotting, and DLS. The results showed that M2 macrophage exosomes significantly attenuated the inflammatory response and pathological damage of articular cartilage in KOA rats. In addition, a key protein associated with KOA including Aggrecan, Col-10, SOX6, and Runx2 was significantly increased, while MMP-13 was significantly suppressed following treatment with M2 macrophage exosomes. The present study indicated that M2 macrophage exosomes exerted protective effects on KOA rats mainly mediated by the PI3K/AKT/mTOR signal pathway. These findings provide a novel approach for the treatment of KOA.


Assuntos
Exossomos/metabolismo , Macrófagos/metabolismo , Osteoartrite do Joelho/metabolismo , Fosfatidilinositol 3-Quinases/metabolismo , Proteínas Proto-Oncogênicas c-akt/metabolismo , Transdução de Sinais/fisiologia , Serina-Treonina Quinases TOR/metabolismo , Animais , Modelos Animais de Doenças , Inflamação/metabolismo , Masculino , Ratos , Ratos Sprague-Dawley
3.
Exp Biol Med (Maywood) ; 240(4): 546-55, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25724194

RESUMO

Epigenetic changes have been recently recognized as important in many human cancers. Enhancer of zeste homologue 2 (EZH2) gene has shown overexpression in various human cancers, consistent with a straightforward role of EZH2 as an oncogene, but its function in carcinogenesis is partly contradictory. The role of EZH2 in development of human colorectal cancer (CRC) has not yet been clarified. In present study, we observed up-regulation of EZH2 expression in tumor tissues from CRC patients. The expression of EZH2 in CRC cell lines is consistent with the trend in cancer tissues using RT-PCR. We showed that TNM stage and lymph node metastasis in CRC patients are significantly correlated with EZH2 expression levels. EZH2 level of transcription and protein was inhibited by small interfering RNA (siRNA). More importantly, EZH2-siRNA inhibited the proliferation and migration of SW620 cells while promoting their apoptosis, and inducing G0/G1 cell cycle arrest of CRC cells. Collectively, our results suggest that up-regulated EZH2 expression may contribute to the progression of the patients with CRC. A comprehensive study of epigenetic mechanisms and the relevance of EZH2 in CRC is important for fully understanding this disease and as a basis for developing new treatment options in patients with CRC.

4.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-820462

RESUMO

OBJECTIVE@#To investigate the expression of HIP/PAP in hepatocellular carcinoma (HCC) patients and explore its role in migration and invasion of HCC.@*METHODS@#The expression of HIP/PAP in HCC tissue and corresponding adjacent noncancerous tissue was assessed by IHC, RT-PCR and Western blot. The correlation between clinicopathological features and HIP/PAP expression was analyzed. The role of HIP/PAP on invasion and migration of HCC cells was observed by RNA interference, wound healing and Transwell assay.@*RESULTS@#Both mRNA and protein expression of HIP/PAP was upregulated in HCC tissues compared to tumor-adjacent tissue and correlated with poor tumor differentiation, advanced tumor stage and vascular invasion. HIP/PAP expression was also upregulated in HCC cells, and silencing its expression by specific siRNA could inhibit the invasion and migration of HCC cells.@*CONCLUSIONS@#HIP/APA is overexpressed in HCC and contributes to the migration and invasion of HCC cells.

5.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-951665

RESUMO

Objective: To investigate the expression of HIP/PAP in hepatocellular carcinoma (HCC) patients and explore its role in migration and invasion of HCC. Methods: The expression of HIP/PAP in HCC tissue and corresponding adjacent noncancerous tissue was assessed by IHC, RT-PCR and Western blot. The correlation between clinicopathological features and HIP/PAP expression was analyzed. The role of HIP/PAP on invasion and migration of HCC cells was observed by RNA interference, wound healing and Transwell assay. Results: Both mRNA and protein expression of HIP/PAP was upregulated in HCC tissues compared to tumor-adjacent tissue and correlated with poor tumor differentiation, advanced tumor stage and vascular invasion. HIP/PAP expression was also upregulated in HCC cells, and silencing its expression by specific siRNA could inhibit the invasion and migration of HCC cells. Conclusions: HIP/APA is overexpressed in HCC and contributes to the migration and invasion of HCC cells.

6.
Chinese Journal of Oncology ; (12): 410-414, 2010.
Artigo em Chinês | WPRIM (Pacífico Ocidental) | ID: wpr-260389

RESUMO

<p><b>OBJECTIVE</b>To investigate if granulocyte-macrophage colony stimulating factor (GM-CSF) gene-modified dendritic cells (DC) enhance antitumor immunity in vitro.</p><p><b>METHODS</b>Mice were injected with chemokine ligand 3 (CCL3) via the tail vein. Fresh B220(-)CD11c(+) cells were sorted from the peripheral blood mononuclear cells (PBMCs) and cultured into DCs by cytokines.DCs were transfected with AdGM-CSF gene at different ratios of multiplicity of infection (MOI) to determine the optimal gene transfection conditions, and the expression of GM-CSF was detected after transfection. The variation of GM-CSF gene-modifiedDCs were analyzed by morphological examination, phenotype analysis, and mixed lymphocyte reaction (MLR).DCs were loaded with gastric cancer antigen obtained by freezing and thawing method. The killing effect of DCs vaccine-stimulated T lymphocytes on gastric cancer cells was assessed by MTT assay. INF-gamma production was determined with the INF-gamma ELISA kit.</p><p><b>RESULTS</b>B220(-)CD11c(+) cells increased obviously after CCL3 injection. The ELISA results showed that after GM-CSF gene modification, DCs could produce high level of GM-CSF. When DCs were transfected with AdGM-CSF gene at MOI equal to 100, the GM-CSF level in culture supernatants reached saturation [(130.00 +/- 12.61) pg/ml]. After GM-CSF gene-modification, DCs tend to be more maturated as detected by morphological observation and phenotype analysis. At the same time, the capacity of activating the proliferation of allogeneic T lymphocytes was enhanced greatly. T lymphocytes stimulated by DCs transfected with GM-CSF gene showed a specific killing effect on gastric carcinoma cells and produced high level of INF-gamma [(1245.00 +/- 13.75) pg/ml].</p><p><b>CONCLUSION</b>After GM-CSF gene modification, DCs can produce high level of GM-CSF, which tend to be more maturated, and the capacity of activating the proliferation of allogeneic T lymphocytes is enhanced greatly. GM-CSF gene modified DCs can induce specific CTL to target tumor cells in vitro.</p>


Assuntos
Animais , Feminino , Camundongos , Adenoviridae , Genética , Antígeno B7-1 , Metabolismo , Antígeno B7-2 , Metabolismo , Antígenos CD40 , Metabolismo , Vacinas Anticâncer , Alergia e Imunologia , Linhagem Celular Tumoral , Proliferação de Células , Citotoxicidade Imunológica , Células Dendríticas , Biologia Celular , Alergia e Imunologia , Metabolismo , Fator Estimulador de Colônias de Granulócitos e Macrófagos , Genética , Metabolismo , Antígenos de Histocompatibilidade Classe II , Metabolismo , Interferon gama , Secreções Corporais , Camundongos Endogâmicos BALB C , Proteínas Recombinantes , Neoplasias Gástricas , Alergia e Imunologia , Metabolismo , Patologia , Linfócitos T Citotóxicos , Biologia Celular , Alergia e Imunologia , Transfecção
7.
Chinese Medical Journal ; (24): 2031-2036, 2008.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-350757

RESUMO

<p><b>BACKGROUND</b>Pancreatic cancer is a highly malignant tumor affecting an ever increasing number of patients with a mean 5-year survival rate below 4%. Therefore, gene therapy for cancer has become a potential novel therapeutic modality. In this study we sought to determine the inhibitory effects of adenovirus-mediated human interleukin-24 (AdhIL-24) on pancreatic cancer.</p><p><b>METHODS</b>Human interleukin-24 gene was cloned into replication-defective adenovirus specific for patu8988 tumor cells by virus recombination technology. Reverse transcription-polymerase chain reaction and Western blotting analysis were used to determine the expression of human interleukin-24 mRNA in patu8988 cells in vitro. Induction of apoptosis by overexpression of human interleukin-24 in patu8988 cells was determined by flow cytometry. In vivo efficacy of adenoviral delivery of human interleukin-24 was assessed in nude mice (n = 10 for each group) bearing patu8988 pancreatic cancer cell lines by determining inhibition of tumor growth, endothelial growth factor and CD34 expression, and intratumoral microvessel density (MVD).</p><p><b>RESULTS</b>The recombinant adenovirus vector AdVGFP/IL-24 was constructed with a packaged recombinant retrovirus titer of 1.0 x 10(10) pfu/ml and successfully expressed of both mRNA and protein in patu8988 cells. The AdVGFP/IL-24 induced apoptosis of patu8988 tumor cells in vitro and significantly inhibited tumor growth in vivo (P < 0.05). The intratumoral MVD decreased significantly in the treated tumors (P < 0.05).</p><p><b>CONCLUSION</b>The recombinant adenovirus AdGFP/IL-24 can effectively express biologically active human interleukin-24, which results in inhibition of pancreatic cancer growth.</p>


Assuntos
Animais , Humanos , Masculino , Camundongos , Adenoviridae , Genética , Antígenos CD34 , Western Blotting , Citometria de Fluxo , Terapia Genética , Vetores Genéticos , Interleucinas , Genética , Camundongos Endogâmicos BALB C , Neoplasias Pancreáticas , Patologia , Terapêutica , Transfecção , Fator A de Crescimento do Endotélio Vascular
8.
Chinese Medical Journal ; (24): 2258-2264, 2008.
Artigo em Inglês | WPRIM (Pacífico Ocidental) | ID: wpr-350731

RESUMO

<p><b>BACKGROUND</b>Transcription factors hypoxia inducible factor 1alpha (HIF 1alpha) and endothelial PAS domain protein 1 (EPAS1) promote the transcription of vascular endothelial growth factor (VEGF). VEGF enhances angiogenesis and vascular permeability of tumours, which promotes tumour growth and facilitates entry of cancer cells into blood circulation and metastasizing. This study examined whether HIF 1alpha and EPAS1 stimulated angiogenesis through activation of VEGF in human pancreatic carcinoma.</p><p><b>METHODS</b>Specimens from pancreatic carcinoma and healthy parts of same pancreas were taken from 60 patients. Real time quantitative reverse transcription polymerase chain reaction estimated expression of HIF 1alpha, EPAS1, and VEGF mRNAs. Western blotting and immunohistochemical, streptavidin peroxidase method assessed expression of HIF 1alpha, EPAS1, and VEGF proteins. Microvessel density (MVD) was assessed.</p><p><b>RESULTS</b>Highly significant increases in expression of EPAS1, VEGF, and MVD were found in pancreatic carcinoma tissue but not in normal pancreatic tissue: VEGF at mRNA and protein levels (t = 17.32, P = 0.0001; t = 98.41, P = 0.0001); EPAS1 protein level (t = 22.51, P = 0.0001). Expression of HIF 1alpha was similar in pancreatic carcinoma and normal pancreatic tissues at both mRNA and protein levels. Significant correlations were observed between EPAS1 and VEGF (r = 0.736, P = 0.0041), between VEGF and MVD (r = 0.858, P = 0.0001), and between EPAS1 and MVD (r = 0.641, P = 0.0003). No significant correlations were observed between HIF 1alpha and VEGF, or between HIF 1alpha and MVD. MVD and expression of EPAS1 and VEGF were significantly related with TNM staging, so was EPASI and VEGF with size of tumour.</p><p><b>CONCLUSIONS</b>EPAS1 and VEGF, but not HIF1alpha, are overexpressed in pancreatic carcinoma. The expression of EPAS1 is correlated with that of VEGF and MVD. EPAS1 may be involved in the angiogenesis of pancreatic carcinoma by upregulating the expression of VEGF. Targeting EPAS1 may be a new method of antiangiogenic tumour therapy for pancreatic carcinoma.</p>


Assuntos
Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Adulto Jovem , Fatores de Transcrição Hélice-Alça-Hélice Básicos , Genética , Metabolismo , Fisiologia , Western Blotting , Regulação Neoplásica da Expressão Gênica , Subunidade alfa do Fator 1 Induzível por Hipóxia , Genética , Metabolismo , Imuno-Histoquímica , Neoplasias Pancreáticas , Genética , Metabolismo , Patologia , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Fator A de Crescimento do Endotélio Vascular , Genética , Metabolismo , Fisiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...